nach oben

Drug Safety

Erschienen in:

01.07.2012 | Review Article

Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy

verfasst von: Professor Renzo Guerrini, Gaetano Zaccara, Giancarlo la Marca, Anna Rosati

Erschienen in: Drug Safety | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of treating epilepsy is to control or at least decrease seizures without producing unacceptable adverse effects that impair quality of life. Antiepileptic drugs (AEDs) have been considered amongst the drugs most frequently associated with fatal suspected adverse drug reactions. Physicians must therefore be as familiar with safety and tolerability data of AEDs as they are with the expected therapeutic effects.

AEDs may cause dose-related adverse effects (i.e. drowsiness, fatigue, dizziness, blurry vision and incoordination) that, in most cases, may be obviated by lowering the dosage, reducing the number of drugs or switching to a better tolerated AED. AEDs also have the potential of precipitating idiosyncratic adverse effects (i.e. serious cutaneous, haematological and hepatic events), which are more common in children and usually require withdrawal of the AED. Although occurrence of idiosyncratic adverse effects can only rarely be predicted or prevented, there are known risk factors that can help in identifying patients at high risk. Occurrence of an idiosyncratic event in a close relative, a concomitant autoimmune disease, co-treatment with specific drugs, history of a previous allergic drug reaction, starting treatment with high doses and rapid titration have all been associated with a higher risk of idiosyncratic adverse effects.

New AEDs have been developed in the last two decades with the aim of improving the benefit-risk balance of AED therapy. Available evidence suggests that the newer AEDs are no more effective but may be somewhat better tolerated than older molecules.

We performed a literature review with the aim of evaluating safety and tolerability of second- and third-generation AEDs in children. A PubMed search was conducted with the purpose of identifying English-language studies published between 1 January 1989 and 1 January 2011 that reported any adverse event having occurred in children with epilepsy in whom second- and third-generation AEDs were administered.

Clarkson A, Chaoonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87: 462–7PubMedCrossRef

Connock M, Frew E, Evans BW, et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review. Health Technol Assess 2006; 10: iii, ix–118

Chu-Store C, Thiele EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol 2010; 17: 214–23CrossRef

Johann-Liang R, Pharm JW, Chen M, et al. Pediatric drug surveillance and the food and drug administration’s adverse event reporting system: an overview of reports, 2003-2007. Pharmacoepidemiol Drug Saf 2009; 18: 24–7PubMedCrossRef

Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007; 161: 282–90PubMedCrossRef

Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2009; 22: 739–60CrossRef

Gillham R, Baker G, Thompson R, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatment. Epilepsy Res 1996; 24: 47–55PubMedCrossRef

Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39 Suppl. 3: S2–10PubMedCrossRef

Gayatri NA, Livingston JH. Aggravation of epilepsy by anti-epileptic drugs. Dev Med Child Neurol 2006; 48: 394–8PubMedCrossRef

10.

Parmeggiani L, Seri S, Bonanni P, et al. Electrophysiological characterization of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes. Clin Neurophysiol 2004; 115: 50–8PubMedCrossRef

11.

Asconape J, Diedrich A, Della Badia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000; 41: 479–81PubMedCrossRef

12.

Lortie A, Chiron C, Mumford J, et al. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993; 43 Suppl. 5: S24–7PubMed

13.

Guerrini R, Belmonte A, Parmeggiani L, et al. Myoclonic status epilepticus following high dose lamotrigine therapy. Brain Dev 1999; 21: 420–4PubMedCrossRef

14.

Cerminara C, Montanaro ML, Curatolo P, et al. Lamo-trigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology 2004; 63: 373–5PubMedCrossRef

15.

Chapman K, Holland K, Erenberg G. Seizure exacerbation associated with oxcarbazepine in idiopathic focal epilepsy of childhood. Neurology 2003; 61: 1012–3PubMedCrossRef

16.

Gelisse P, Genton P, Kuate C, et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 1282–6PubMedCrossRef

17.

Kaddurah AK, Holmes GL. Possible precipitation of myoclonic seizures with oxcarbazepine. Epilepsy Behav 2006; 8: 289–93PubMedCrossRef

18.

Skardoutsou A, Voudris KA, Vagiakou EA. Non-convulsive status epilepticus associated with tiagabine therapy in children. Seizure 2003; 12: 599–601PubMedCrossRef

19.

Ferrendelli JA. Concern with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 2001; 42 Suppl 4: 28–30PubMedCrossRef

20.

Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45: 1061–75PubMedCrossRef

21.

Krasowski M. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals 2010; 3: 1909–35PubMed

22.

Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239–76PubMedCrossRef

23.

Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347–56PubMedCrossRef

24.

Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010; 10: 119–40PubMedCrossRef

25.

Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183–7PubMedCrossRef

26.

Novy J, Patsalos PN, Sander JW, et al. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011; 20: 20–3PubMedCrossRef

27.

Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41: 961–4PubMedCrossRef

28.

Camfield P, Camfield C. Monitoring for adverse effects of antiepileptic drugs. Epilepsia 2006; 47 Suppl. 1: 31–4PubMedCrossRef

29.

Bourgeois BF. Determining the effects of antiepileptic drugs on cognitive function in pediatric patients with epilepsy. J Child Neurol 2004; Suppl 1: 15–24

30.

Korn-Merker E, Borusiak P, Boenigk HE. Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. Epilepsy Res 2000; 39: 27–32CrossRef

31.

Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicenter, open-label study. Dev Med Child Neurol 2001; 43: 269–73PubMedCrossRef

32.

Levisohn PM, Mintz M, Hunter SJ, et al. Neurocognitive effects of adjunctive levetiracetam in children with partialonset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009; 50: 2377–89PubMedCrossRef

33.

Martinez W, Ingenito A, Blakeslee M, et al. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy Behav 2006; 9: 448–56PubMedCrossRef

34.

Wier HA, Cerna A, So TY. Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. Paediatr Drugs 2011; 13(2): 97–106PubMedCrossRef

35.

Uldall P, Bulteau C, Pedersen SA, et al. Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res 2000; 42: 159–68PubMedCrossRef

36.

Rosenfeld WE, Doose DR, Walker SA, et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999; 20: 339–44PubMedCrossRef

37.

Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005; 112: 214–22PubMedCrossRef

38.

Kluger G, Zsoter A, Holthausen H. Long-term of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol 2008; 12: 19–23PubMedCrossRef

39.

Grosso S, Cordelli DM, Coppola G, et al. Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. Eur J Neurol 2008; 15: 940–6PubMedCrossRef

40.

Gavatha M, Ioannou I, Papavasiliou SA. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 2001; 20: 691–3CrossRef

41.

Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999; 40: 1618–26PubMedCrossRef

42.

Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356(9242): 1638–42PubMedCrossRef

43.

Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 2009; 50: 2362–8PubMedCrossRef

44.

Bourgeois BF, D’Souza J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav 2005; 7: 375–82PubMedCrossRef

45.

Northam RS, Hernandes AW, Litzinger MJ, et al. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol 2005; 33: 337–44PubMedCrossRef

46.

Jan MM, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol 2009; 40: 347–50PubMedCrossRef

47.

Wheless JW, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24: 1520–5PubMedCrossRef

48.

Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center’s experience. Pediatr Neurol 2010; 43: 155–8PubMedCrossRef

49.

Cho YJ, Heo K, Kim WJ, et al. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 2009; 50: 1910–9PubMedCrossRef

50.

Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009; 13: 3–9PubMedCrossRef

51.

Dalla Bernardina B, Fontana E, Vigevano F, et al. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia 1995; 36: 687–91PubMedCrossRef

52.

Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure 2000; 9: 137–41PubMedCrossRef

53.

Guilhoto LM, Loddenkemper T, Gooty VD, et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2001; 55: 414–9

54.

Gross-Tsur V, Shalev RS. Reversible language regression as an adverse effect of topiramate treatment in children. Neurology 2004; 62: 299–300PubMedCrossRef

55.

Gay PE, Mechman GF, Coskey JS, et al. Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Psychol Rep 1995; 77: 1208–10PubMedCrossRef

56.

Mikati MA, Choueri R, Khurana DS, et al. Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res 1998; 42 Suppl 1: 57–62PubMed

57.

Ferrie CD, Robinson RO, Panayiotopoulos CP. Psychotic and severe behavioural reactions with vigabatrin: a review. Acta Neurol Scand 1996; 93: 1–8PubMedCrossRef

58.

Verrotti A, D’Adamo E, Parisi P, et al. Levetiracetam in childhood epilepsy. Paediatr Drugs 2010; 12: 177–86PubMedCrossRef

59.

Das KB, Harris C, Smyth DP, et al. Unusual side effects of lamotrigine therapy. J Child Neurol 2003; 18: 479–80PubMedCrossRef

60.

Piña-Garza JE, Elterman RD, Ayala R, et al. Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old. J Child Neurol 2008; 23: 853–61PubMedCrossRef

61.

Sackellares JC, Krauss G, Sommerville KW, et al. Occurrence of psychosis in patients in patients with epilepsy randomzed to tiagabine or placebo treatment. Epilepsia 2002; 43: 394–8PubMedCrossRef

62.

Messnheimer J. Efficacy and safety of lamotrigine in pediatric patients. J Child Neurol 2002; 17 Suppl 2: 34–42

63.

Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008; 49: 108–16PubMedCrossRef

64.

Kerrick JM, Kelly BJ, Maister BH, et al. Involuntary movement disorders associated with felbamate. Neurology 1995; 45: 185–7PubMedCrossRef

65.

Zesiewicz TA, Sullivan KL, Hauser RA. Chorea induced by lamotrigine [letter]. J Child Neurol 2006; 21: 357PubMed

66.

Sotero De Menezes MA, Rho JM, Murphy P, et al. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia 2000; 41: 862–7CrossRef

67.

Gijsen VM, de Wildt SN, Ito S. Probability of rash related to gabapentin therapy in a child. Ann Pharmacother 2009; 43: 387–9PubMed

68.

Dooley J, Camfield P, Gordon K, et al. Lamotrigine-induced rash in children. Neurology 1996; 46: 240–2PubMedCrossRef

69.

Kim SC, Seol IJ, Kim SJ. Hypohidrosis-related symptoms in pediatric epileptic patients with topiramate. Pediatr Int 2010; 52: 109–12PubMedCrossRef

70.

Sparagana SP, Strand WR, Adams RC. Felbamate urolithiasis. Epilepsia 2001; 42: 682–5PubMedCrossRef

71.

Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67 Suppl. 4: 28–33CrossRef

72.

Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009; 50: 184–94PubMedCrossRef

73.

Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009; 50: 195–205PubMedCrossRef

74.

Thelle T, Gammelgaard L, Hansen JK, et al. Reversible magnetic resonance imaging and spectroscopy abnormalities in the course of vigabatrin treatment for West syndrome. Eur J Paediatr Neurol 2011; 15: 260–4PubMedCrossRef

75.

Beran RG, Berkovic S, Buchanan N, et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996; 5: 259–65PubMedCrossRef

76.

Sachdeo R, Narang-Sachdeo SK, Shumaker RC, et al. Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200–6,000 mg/day in subjects with epilepsy. Epilepsia 1997; 38: 887–92PubMedCrossRef

77.

Paul E, Conont KD, Dunne IE, et al. Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. Epilepsy Res 2010; 90: 151–6PubMedCrossRef

78.

Albsoul-Younes AM, Lasem Ha, Ajlouni SF, et al. Topiramate slow titration: improved efficacy and tolerability. Pediatr Neurol 2004; 31: 349–52PubMedCrossRef

79.

Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999; 33: 1037–42PubMedCrossRef

80.

Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48: 1223–44PubMedCrossRef

81.

Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolites formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002; 3: 367–77PubMedCrossRef

82.

Sadeque AJM, Fisher MB, Korzekwa KR, et al. Human CYP2C9 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997; 283: 698–703PubMed

83.

Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 2003; 192: 37–48PubMedCrossRef

84.

Walgren JL, Mitchell MD, Thomson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005; 35: 325–61PubMedCrossRef

85.

Park BK, Pirmohamed M, Kitteringham NR. The role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective. Chem Res Toxicol 1998; 11: 969–88PubMedCrossRef

86.

Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987; 36: 581–90PubMedCrossRef

87.

Uetrecht J. Newconceptsinimmunologyrelevantto idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol 1999; 12: 387–95PubMedCrossRef

88.

Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301–5PubMedCrossRef

89.

Guengerich FP. Cytochrome P450 and other enzymes in drug metabolism and toxicity. AAPS J 2006; 8(1): E101–11PubMedCrossRef

90.

Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002; 43 Suppl. 3: 53–9PubMedCrossRef

91.

Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionalde-hyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol 1996; 9: 1225–9PubMedCrossRef

92.

Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem Res Toxicol 1997; 10: 457–62PubMedCrossRef

93.

Kapetanovic IM, Torchin CD, Strong JM, et al. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact 2002; 142: 119–34PubMedCrossRef

94.

Dieckhaus CM, Roller SG, Santos WL, et al. Role of glutathione S-transferases A1-1, M1-1, and P1-1 in the detoxification of 2-phenylpropenal, a reactive felbamate metabolite. Chem Res Toxicol 2001; 14: 511–6PubMedCrossRef

95.

Popovic M, Nierkens S, Pieters R, et al. Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. Chem Res Toxicol 2004; 17: 1568–76PubMedCrossRef

96.

Pellock JM, Faught E, Leppik IE, et al. Felbamate: consensus of current clinical experience. Epilepsy Res 2006; 71: 89–101PubMedCrossRef

97.

Zaccara G, Cincotta M, Borgheresi A, et al. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord 2004; 6: 153–68PubMed

98.

Masmoudi K, Gras-Champel V, Masson H, et al. Parkin-sonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006; 39: 9–12PubMedCrossRef

99.

Guerrini R, Belmonte A, Canapicchi R, et al. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 1998; 39: 27–32PubMedCrossRef

100.

Edwards SG, Hubbard V, Aylett S, et al. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad Med 1999; 75: 680–1CrossRef

101.

Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro risk assessment. J Clin Invest 1988; 82: 1826–32PubMedCrossRef

102.

Ferrell Jr PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9(10): 1543–6PubMedCrossRef

103.

Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486PubMedCrossRef

104.

Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987; 28: S23–9PubMedCrossRef

105.

Perucca E. Clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45: 351–63PubMedCrossRef

106.

Stewart JD, Horvath R, Baruffini E, et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010; 52: 1791–6PubMedCrossRef

107.

Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities: II. US experience since 1984. Neurology 1989; 139: 201–7CrossRef

108.

Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008; 71: 1527–34PubMedCrossRef

109.

Peyrière H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155: 422–8PubMedCrossRef

110.

Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353: 2190–4PubMedCrossRef

111.

Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160–5PubMedCrossRef

112.

Binaghi M, Koso M, Saiag P, et al. Ocular involvement in Lyell’s syndrome: incidence, evolution, prognosis. Oph-talmologie 1988; 2: 121–2

113.

Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839–42PubMedCrossRef

114.

Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272–85PubMedCrossRef

115.

Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92–6PubMedCrossRef

116.

Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38: 1265–9PubMedCrossRef

117.

Blackbum SC, Oliart D, Garcia RL, et al. Antiepileptic and blood dyscrasia; a cohort study. Pharmacotherapy 1998; 18: 1277–83

118.

Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38 Suppl. 2: S44–8PubMedCrossRef

119.

Binek J, Hany A, Heer M. Valproic acid-induced pancreatitis: report of a case and review of literature. J Clin Gastroenterol 1991; 13: 690–3PubMedCrossRef

120.

Zaccara G, Campostrini R, Paganini M, et al. Acute changes of blood ammonia may predict short-term effects of valproic acid. Neurology 1984; 34: 1519–21PubMedCrossRef

121.

Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 1993; 8: 19–27PubMedCrossRef

122.

Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate, associated, acute, secondary angle-closure glaucoma. Ophthalmology 2004; 111: 109–11PubMedCrossRef

123.

Watanabe T, Yoshikawa H, Yamazaki S, et al. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 2005; 20: 814–7PubMedCrossRef

124.

Guerrini R. Epilepsy in children. Lancet 2006; 367: 499–524PubMedCrossRef

125.

Sulzbacher S, Farwell JR, Temkin N, et al. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr 1999; 38: 387–94CrossRef

126.

Donati F, Gobbi G, Campistol J, et al. The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure 2007; 16: 670–9PubMedCrossRef

127.

Kang HC, Eun BL, Wu LC, et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia 2007; 48: 1716–23PubMedCrossRef

128.

Bootsma HP, Aldenkamp AP, Diepman L, et al. The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia 2006; 47 Suppl. 2: 24–7PubMedCrossRef

129.

Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611–3PubMedCrossRef

130.

Best JL, Acheson JF. The natural history of vigabatrin associated visual field defects in patients electing to continue their medication. Eye 2005; 19: 41–4PubMedCrossRef

131.

Kraemer G, Ried S, Landau K, et al. Vigabatrin: reversibility of severe concentric visual field defects after early detection and drug withdrawal. A case report. Epilepsia 2000; 41 Suppl.: 144CrossRef

132.

Guideline for prescribing vigabatrin in children has been revised. Vigabatrin Paediatric Advisory Group. BMJ 2000; 320(7246): 1404–5CrossRef

133.

Nousiainen I, Mantyjarvi M, Kälviäinen R. No reversion in vigabatrin-associated field defects. Neurology 2001; 57: 1916–7PubMedCrossRef

Titel: Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy
verfasst von: Professor Renzo Guerrini
Gaetano Zaccara
Giancarlo la Marca
Anna Rosati
Publikationsdatum: 01.07.2012
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 7/2012
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/11630700-000000000-00000

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Examination of Baseline Risk Factors for QTc Interval Prolongation in Patients Prescribed Intravenous Haloperidol

Impact of Regulatory Guidances and Drug Regulation on Risk Minimization Interventions in Drug Safety

Aconite Poisoning over 5 Years

Analysis of Event Logs from Syringe Pumps

The Outcomes of Pregnancy in Women Exposed to the New Macrolides in the First Trimester

The Safety of H1N1 Vaccine in Children in Saudi Arabia